Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
South Africa: Litigation threat may prompt access to cheaper DR-TB drug

South Africa may finally allow access to a cheaper form of the drug-resistant tuberculosis (DR-TB) drug linezolid following the lodging of a high court case.

Published
16 June 2014
From
Health-e
South Africa: Government to introduce new drug-resistant TB drugs

Government’s small-scale introduction of the first new TB drug in four decades is saving lines and paving the way for more, better and cheaper drugs to treat drug-resistant TB. Many wonder if they will come fast enough for those who need them.

Published
16 June 2014
From
Health-e
South African activists: DR-TB a ‘public health emergency’

Civil society groups have called for government to declare drug-resistant tuberculosis (DR-TB) a public health emergency, as the DR-TB response remains underfunded.

Published
16 June 2014
From
Health-e
South Africa: Antiretrovirals Credited for TB Decline

South Africa is seeing about 79,000 fewer TB cases annually thanks to increased HIV treatment uptake, according to the latest research from the National Institute for Communicable Diseases (NCID)

Published
13 June 2014
From
Health-e
An activist's guide to TB drugs

TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.

Published
04 June 2014
From
TAG
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

Last week’s important developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility.

Published
14 May 2014
From
Science Speaks
UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Breakthrough new medicines for hepatitis C and drug-resistant TB and largest-yet global programme for seasonal malaria chemoprevention to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID

Published
07 May 2014
From
UNITAID
Lab-Confirmed HIV Rate 33% Among Kenyans With Prior Tuberculosis

Among Kenyans with prior tuberculosis, one third had lab-confirmed HIV infection, according to results of a nationally representative survey. Adult HIV prevalence stood at 5.6%.

Published
07 May 2014
From
International AIDS Society
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)

First grant of a marketing authorization of Otsuka’s novel drug for multidrug-resistant tuberculosis (MDR-TB).

Published
01 May 2014
From
Otsuka press release

Filter by country